On July 18th, MindRank, a clinical stage AI-empowered drug discovery company, announced today that it has completed over $20 million in A+ round financing, which was led by Cherami Investment Group. Other investors with expertise in the life sciences and healthcare sectors also participated. Pure Spring Capital served as the exclusive financial advisor. This round of financing will be used to advance the company's proprietary innovative drug pipeline, further refine and commercialize its AI platform.
The original news link in Chinese: